Royal Bank of Canada’s OptimizeRx OPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2K | Sell |
262
-1,589
| -86% | -$14.8K | ﹤0.01% | 6739 |
|
|
2025
Q4 | $23K | Sell |
1,851
-1,112
| -38% | -$18.2K | ﹤0.01% | 5967 |
|
|
2025
Q3 | $61K | Buy |
2,963
+1,670
| +129% | +$26.5K | ﹤0.01% | 5739 |
|
|
2025
Q2 | $17K | Sell |
1,293
-2,319
| -64% | -$25.4K | ﹤0.01% | 6322 |
|
|
2025
Q1 | $31K | Sell |
3,612
-19,932
| -85% | -$122K | ﹤0.01% | 5760 |
|
|
2024
Q4 | $115K | Sell |
23,544
-1,775
| -7% | -$9.92K | ﹤0.01% | 5246 |
|
|
2024
Q3 | $196K | Buy |
25,319
+152
| +0.6% | +$1.35K | ﹤0.01% | 4835 |
|
|
2024
Q2 | $252K | Buy |
25,167
+279
| +1% | +$3.06K | ﹤0.01% | 4561 |
|
|
2024
Q1 | $301K | Sell |
24,888
-4,410
| -15% | -$64K | ﹤0.01% | 4349 |
|
|
2023
Q4 | $419K | Buy |
29,298
+1,773
| +6% | +$17K | ﹤0.01% | 4415 |
|
|
2023
Q3 | $215K | Buy |
27,525
+983
| +4% | +$10.7K | ﹤0.01% | 4736 |
|
|
2023
Q2 | $380K | Sell |
26,542
-651
| -2% | -$9.27K | ﹤0.01% | 4163 |
|
|
2023
Q1 | $399K | Sell |
27,193
-1,597
| -6% | -$26.7K | ﹤0.01% | 4056 |
|
|
2022
Q4 | $483K | Sell |
28,790
-23,847
| -45% | -$412K | ﹤0.01% | 4136 |
|
|
2022
Q3 | $780K | Buy |
52,637
+18,446
| +54% | +$365K | ﹤0.01% | 3654 |
|
|
2022
Q2 | $937K | Buy |
34,191
+1,636
| +5% | +$48.5K | ﹤0.01% | 3566 |
|
|
2022
Q1 | $1.23M | Sell |
32,555
-95
| -0.3% | -$4.21K | ﹤0.01% | 3475 |
|
|
2021
Q4 | $2.03M | Buy |
32,650
+675
| +2% | +$51.1K | ﹤0.01% | 3144 |
|
|
2021
Q3 | $2.74M | Sell |
31,975
-797
| -2% | -$50K | ﹤0.01% | 2818 |
|
|
2021
Q2 | $2.03M | Buy |
32,772
+7,167
| +28% | +$365K | ﹤0.01% | 3059 |
|
|
2021
Q1 | $1.25M | Buy |
25,605
+10,761
| +72% | +$519K | ﹤0.01% | 3388 |
|
|
2020
Q4 | $462K | Buy |
14,844
+5,571
| +60% | +$136K | ﹤0.01% | 4208 |
|
|
2020
Q3 | $194K | Buy |
9,273
+208
| +2% | +$3.57K | ﹤0.01% | 4574 |
|
|
2020
Q2 | $118K | Buy |
9,065
+6,690
| +282% | +$72.7K | ﹤0.01% | 4755 |
|
|
2020
Q1 | $21K | Sell |
2,375
-850
| -26% | -$8.06K | ﹤0.01% | 5519 |
|
|
2019
Q4 | $33K | Buy |
3,225
+891
| +38% | +$10.1K | ﹤0.01% | 5643 |
|
|
2019
Q3 | $34K | Sell |
2,334
-260
| -10% | -$4.02K | ﹤0.01% | 5276 |
|
|
2019
Q2 | $42K | Buy |
2,594
+260
| +11% | +$3.51K | ﹤0.01% | 5363 |
|
|
2019
Q1 | $30K | Hold |
2,334
| – | – | ﹤0.01% | 5443 |
|
|
2018
Q4 | $26K | Hold |
2,334
| – | – | ﹤0.01% | 5457 |
|
|
2018
Q3 | $42K | Hold |
2,334
| – | – | ﹤0.01% | 5322 |
|
|
2018
Q2 | $24K | Buy |
+2,334
| New | +$24K | ﹤0.01% | 5462 |
|
Other funds holding OPRX
WCA
RA
PHP
VCM
KCM
RHJA
Royal Bank of Canada's OPRX Position: Q1 2026 in Review
Royal Bank of Canada reduced its OptimizeRx (OPRX) stake by 86% in Q1 2026, selling an estimated $14.8K and leaving 262 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #6739.
Royal Bank of Canada first reported a position in OPRX in Q2 2018 and has held it in 32 quarters since. The position peaked at $2.74M in Q3 2021. 127 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.
- Royal Bank of Canada held 262 shares of OptimizeRx worth $2K as of Q1 2026.
- Royal Bank of Canada sold 1,589 OptimizeRx shares in Q1 2026, an estimated $14.8K.
- OptimizeRx made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6739 holding.
- Royal Bank of Canada first reported a position in OptimizeRx in Q2 2018 and has held it in 32 quarters since.
- Royal Bank of Canada's OptimizeRx position peaked at $2.74M in Q3 2021.
- 127 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.